BlackRock Closed-End Funds
POLÍTICA

BlackRock Enhanced Government Fund, Inc. Announces Expiration of Annual Repurchase Offer

BlackRock Enhanced Government Fund, Inc. (NYSE: EGF) has completed its annual repurchase offer, which expired on November 15, 2024. The offer allowed for repurchase of up to 5% of outstanding shares at net asset value, subject to a 2% fee. Preliminary results indicate oversubscription, with approximately 12% of shares tendered, necessitating pro rata allocation. Shares held by stockholders with 99 or fewer shares who tendered all shares will be fully repurchased. Final results will be confirmed soon.

Kahn Swick & Foti
NOTICIAS

ASML HOLDING SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ASML Holding N.V. – ASML

Kahn Swick & Foti, LLC (“KSF”) reminds investors of a January 14, 2025 deadline to file lead plaintiff applications in a securities class action lawsuit against ASML Holding N.V. (NasdaqGS: ASML). The lawsuit alleges ASML misled investors about its financial health, leading to a 16.3% drop in share price after a disappointing Q3 2024 financial report. The case, City of Hollywood Firefighters’ Pension Fund v. ASML Holding N.V., seeks to recover losses from alleged securities law violations.

Adicet Bio Inc.
NOTICIAS

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio, Inc. (Nasdaq: ACET) announced promising biomarker data from its Phase 1 GLEAN trial for ADI-001, an allogeneic gamma delta CAR T cell therapy targeting CD20+ B cells. Results showcased robust tissue homing, CAR T cell activation, and complete CD19+ B cell depletion in lymphoid tissues. ADI-001 is being studied for six autoimmune diseases, including lupus nephritis (LN) and systemic lupus erythematosus (SLE). The findings will be presented at ACR Convergence 2024. The trial aims to address unmet needs in autoimmune care, with FDA Fast Track Designation for LN.

Rosen Law Firm
NOTICIAS

Rosen Law Firm Urges ASML Holding N.V. (NASDAQ: ASML) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm has filed a class action lawsuit on behalf of investors in ASML Holding N.V. (NASDAQ: ASML) for alleged misstatements regarding the severity of semiconductor industry challenges and recovery pace during the Class Period (January 24, 2024 – October 15, 2024). The lawsuit claims ASML misled investors about market risks, demand reliability, and regulatory impacts, causing investor losses. Eligible shareholders have until January 13, 2025, to file as lead plaintiffs.

Suscribirse al boletín informativo

Email Subscription Form

Copyright © Todas las marcas son propiedad de la respectiva empresa o de BORGES MEDIA INC. Queda prohibida la reproducción total o parcial de cualquiera de los contenidos que aquí aparecen, así como su traducción a cualquier idioma sin autorización escrita de su propietario, la mejor revista de Sacramento. Consulte nuestra  Política de Privacidad.